WO1989003678A1 - Low residual solvent microspheres and microencapsulation process - Google Patents

Low residual solvent microspheres and microencapsulation process Download PDF

Info

Publication number
WO1989003678A1
WO1989003678A1 PCT/US1988/003859 US8803859W WO8903678A1 WO 1989003678 A1 WO1989003678 A1 WO 1989003678A1 US 8803859 W US8803859 W US 8803859W WO 8903678 A1 WO8903678 A1 WO 8903678A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
solvent
core material
oil
εaid
Prior art date
Application number
PCT/US1988/003859
Other languages
French (fr)
Inventor
Danny H. Lewis
J. Daniel Sherman
Original Assignee
Stolle Research & Development Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Research & Development Corporation filed Critical Stolle Research & Development Corporation
Publication of WO1989003678A1 publication Critical patent/WO1989003678A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/06Making microcapsules or microballoons by phase separation
    • B01J13/12Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/20After-treatment of capsule walls, e.g. hardening
    • B01J13/206Hardening; drying

Definitions

  • the present invention relates to a method of icroencapsulating a core material to form a microsphere with reduced residual solvent and water content.
  • Microencapsulation is the process of coating a core material with a thin layer of a separate, encapsulating material to form microcapsules.
  • the microencapsulation process has many applications, particularly in the pharmaceutical industry.
  • drugs are coated to obtain controlled-release of the drug, to improve chemical stability, and to permit the mixing and storage of reactive or incompatible drugs.
  • phase separation process For water-soluble or miscible core material, the phase separation process generally involves the technique of dispersing the solid core material of the desired particle size or an aqueous solution or suspension in a polymeric coating material dissolved in an organic solvent. The polymeric material is then deposited on the core material by gradual precipitation of the polymer.. This is achieved by either the use of precipitants, by changes in tempera ⁇ ture, or by removal of the solvent by dilution or distillation. An example of this process is described in United States Patent No. 4,166,800 to Fong. In this patent, the polymer is precipitated by a phase separa ⁇ tion agent, a non-solvent for the polymer.
  • U.S. Patent No. 4,518,547 to Cuff et al.. describes a process for the microencapsulation of a hydrophilic core material by interfacial polycondensation.
  • the process comprises dissolving the core material in a hydrophilic solvent, water, preferably together with an inert carrier material and adding a water immiscible organic solvent to form droplets containing the core material.
  • Two complementary polycondensation monomer reactants are then added either sequentially or simulta ⁇ neously which causes interfacial polymerization of a membrane encapsulating the core material.
  • U.S. Patent No. 4,384,975 to Fong describes an oil- in-water emulsion process for producing icrospheres. This process comprises dissolving a polymer in a volatile, water-immiscible organic solvent in which the core material is not soluble; adding the core material; mixing the organic dispersion with an aqueous solution containing a carboxylic acid salt as the emulsifier to form a stable oil-in-water emulsion; and removing the organic solvent by evaporation to form the micro ⁇ capsules.
  • U.S. Patent No. 4,389,330 to Tice et al.. describes a process for preparing microcapsules containing a water insoluble core material.
  • a polymer is dissolved in an organic solvent.
  • the core material is dispersed or dissolved in the polymer-organic solvent.
  • This loaded mixture is then dispersed in a continuous- phase processing medium to form the microcapsules.
  • the medium can be water or a non-aqueous media such as xylene or toluene or oils.
  • the solvent is removed in a two-step removal process.
  • European Patent Application No. 81/305426.9 describes a microencapsulation process of water soluble polypeptides.
  • a polymer, the wall- forming material is dissolved in an organic solvent, methylene chloride.
  • the core material is then added to the polymer-solvent solution.
  • a non-solvent such as an oil compound which is soluble in the organic solvent, but is a non-solvent for the polymer is then added.
  • the ratio of non-solvent to organic solvent is about 1:3.
  • the microcapsules that are formed are then quenched by mixing them with heptane.
  • This invention comprises a process for microencap- sulating a core material such that the resulting microcapsule has reduced residual solvent and reduced water content.
  • the microsphere has reduced residual solvent with no residual water present. The process of this invention involves the steps of:
  • the invention also comprises microspheres compris ⁇ ing a core material encapsulated by a polymer coating, the microspheres having a residual solvent content of, about one percent.
  • the inventors have discovered that the use of synthetic oils or vegetable oil compounds as the first non-solvent in combination with the high ratio of the first non-solvent to the organic solvent for the polymeric coating material reduces the residual solvent in the final microsphere product. By use of this invention it is possible to reduce the level of residual solvent in the microspheres.
  • the final microspheres when solid particles to be encapsulated are used, the final microspheres will have a reduced residual solvent with no residual water content.
  • the invention also comprises microspheres comprising a core material encapsulated by a polymer coating, the microspheres having a reduced residual solvent content of about one percent and with no residual water present.
  • the process of this invention is based on a phase separation technique to microencapsulate a core materi ⁇ al.
  • the general process of this invention involves the following steps:
  • the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product.
  • a final microsphere product is produced that has a residual solvent level of less than one percent.
  • residual solvent is meant the level of residual second non- solvent that remains in the final microsphere product.
  • organic solvent typi ⁇ cally ethylene chloride.
  • the methylene chloride level is vacuum extractable to 0.1 % or less.
  • the ratios are based on a weight/weight ratio.
  • the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product.
  • a final microsphere product is produced that has a residual solvent level of less than one percent and a reduced water content.
  • the core material that may be used in this inven ⁇ tion can include any material that is not soluble or miscible with the polymeric coating material or the organic solvent for the polymer or the first or second non-solvent for the polymer.
  • the polymeric coating material that may be used in this invention may be either natural or synthetic polymers, or combinations thereof.
  • the polymers may include cellulosic polymers, polyvinyl acetate, poly ⁇ vinyl alcohol, polyvinyl chloride, natural and synthetic rubbers, polyacrylates, polyorthoesters, and the like.
  • polystyrene ethyl- cellulose, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylaminohydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly- (meth)acrylic acid ester, polyvinylacetal-diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate- etha ⁇ rylic acid copolymer, polycarbonate, polyesters, polypropylene, vinylchloride-vinylacetate copolymer, polysaccharides, and glycerol distearate.
  • Suitable polymers for use with a pharmaceutical core material include biodegradable polymers such as polyanhydrides and aliphatic polyesters including polylactide, polylactide-co-glycolide polyglycolide, polycaprolactone, polylactide-co-caprolactone, poly- hydroxybutyride, polyanhydride, polydioxanone, and copolymers thereof such as poly(lactide-co-glycolide) copolymer and polylactide homopolymer.
  • biodegradable polymers such as polyanhydrides and aliphatic polyesters including polylactide, polylactide-co-glycolide polyglycolide, polycaprolactone, polylactide-co-caprolactone, poly- hydroxybutyride, polyanhydride, polydioxanone, and copolymers thereof such as poly(lactide-co-glycolide) copolymer and polylactide homopolymer.
  • the organic solvent that may be used according to this invention to dissolve the polymeric coating material must be a material which will dissolve the polymeric coating material and which will not dissolve the core material to be encapsulated. If the core material is a pharmaceutical compound, then the organic solvent must also be chemically inert with respect to any pharmaceutical compounds to be encapsulated.
  • the organic solvent can be selected from a variety of common organic solvents including halogenated aliphatic hydrocarbons, typically the C ⁇ to c 4 halo ⁇ genated alkanes, such as, for example, chloroform, methylene chloride, ethylene dichloride, ethylene chloride, ethyl acetate, methylchloroform and the like; aromatic hydrocarbon compounds, halogenated aromatic hydrocarbon compounds; cyclic ethers such as tetrahydro- furan and the like.
  • halogenated aliphatic hydrocarbons typically the C ⁇ to c 4 halo ⁇ genated alkanes, such as, for example, chloroform, methylene chloride, ethylene dichloride, ethylene chloride, ethyl acetate, methylchloroform and the like
  • aromatic hydrocarbon compounds halogenated aromatic hydrocarbon compounds
  • cyclic ethers such as tetrahydro- furan and the like.
  • the first non-solvent for the polymer according to this invention may be selected from synthetic oils or vegetable oil compounds.
  • Synthetic oils may include silicone oil, mineral oil, and petroleum oils.
  • Vege ⁇ table oils may include sesame oil, peanut oil, soybean oil, corn oil, cotton seed oil, coconut oil, linseed oil, and other related oils.
  • non-solvent is meant a solvent that is miscible with the organic solvent but is not a solvent for the polymeric coating or core materi ⁇ al.
  • the inventors have discovered that the amount and type of the first non-solvent for the polymer controls the level of residual solvent (second non-solvent) in the final microsphere product.
  • the ratio of first non-solvent to organic solvent is from about 1:5 to about 3:1. Further, in one embodiment of this invention, by employing solid drug particles rather than aqueous solutions or suspensions of drug, no residual water is present in the final product.
  • the polymeric coating material is dissolved in the selected organic solvent prior to adding the core material.
  • the amount of polymeric coating material dissolved in the solvent is typically from about 5 to 50 percent.
  • the core material is then added to the polymer- solvent solution, preferably, as solid particles to form a suspension or as an aqueous solution to form a water- in-oil emulsion.
  • the amount of core material added to the polymer-solvent solution is not critical, although the ratio of core material to polymer is important insofar as that at too high an amount of core material to polymer, microspheres will not form.
  • the upper limit of the ratio of core material to polymer may be about 80 parts by weight core material to about 20 parts by weight polymer.
  • core material is added to the polymer-solvent solution such that the core material comprises about 5 to 50 weight percent.
  • the first non-solvent synthetic oil or vegetable oil, in an amount of the ratio of about 1:5 to about 3:0, first non-solvent to organic solvent, is then added slowly to the mixture of polymeric solvent solution with the added core material.
  • the first non-solvent causes the polymeric material to precipitate out of the organic solvent onto the core material, thereby encapsulating the core material.
  • the first non-solvent is added under carefully controlled conditions of temperature, rate, and stir speed. For example, temperature conditions may range from -20 degrees C to +30 degrees C; rate 5 g/minutes per g of batch; stir speed from 400 to 2500 rpm.
  • the microspheres are treated in a quenching step to harden them.
  • the microspheres are quenched with a second non-solvent. This second non-solvent hardens the microspheres and extracts the solvent from the microspheres and yet does not dissolve the microspheres (wall material or core material) .
  • the amount of second non-solvent added in this quenching step is typically from about 0.251/g of batch to about 1 1/g of batch.
  • Suitable second non-solvents include heptane and aliphatic hydrocarbons such as hexanes.
  • the microspheres are isolated, such as by filtration or sieving, and are dried by exposure to air or by other conventional drying techniques, such as vacuum drying, drying over a dessicant, or the like.
  • the microspheres are dried under a vacuum at room temperature to further reduce the level of organic solvent in the final microsphere product.
  • the process of this invention a final microsphere product is produced that contains about one percent residual solvent.
  • the inal microsphere product contains about one percent residual solvent with no residual water present.
  • the microsphere product of the present invention is usually made up of particles of a spherical shape although sometimes the microspheres may be irregularly shaped.
  • the microspheres can vary in size, ranging from sub- micron to millimeter diameters. Preferably, ⁇ ubmicron to 250 urn diameters are desirable for pharmaceutical formulations allowing administration of the microspheres with a standard syringe and needle.
  • the microspheres find utility in a wide variety of applications depending upon the encapsulated core compound.
  • the microsphere product, according to this invention is an encapsulated pharmaceutical compound which can be administered to both humans and animals.
  • the core material that may be used in the process of this invention may include agricultural agents, such as insecticides, fungicides, herbicides, rodenticides, pesticides, fertilizers, and viruses for crop protection and the like; cosmetic agents, such as deodorants, fragrances, and the like; food additives such as flavors; and pharmaceutical agents.
  • Pharmaceutical compounds are the preferred core materials of the process according to this invention. These compounds may also include the non-toxic pharma ⁇ ceutically acceptable acid addition salts, such as hydrochloride, ⁇ ulfate, phosphate, succinate, benzoate, acetate, pamoate, fu erate, mesylate, and the like.
  • non-toxic pharma ⁇ ceutically acceptable acid addition salts such as hydrochloride, ⁇ ulfate, phosphate, succinate, benzoate, acetate, pamoate, fu erate, mesylate, and the like.
  • contraceptive agents including estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol, and the like; progestins such as norethindrone, norgestryl, ethynodiol diacetate, lynestrenol, medroxyprogesterone acetate, dimethi- sterone, megestrol acetate, chlormadinone acetate, norgestimate, norethisterone, ethisterone, melengestrol, norethynodrel and the like; and spermicidal compounds such as nonylphenoxypolyoxyethylene glycol, benzethoniu chloride, chlorindanol and the like.
  • estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol,
  • gastrointestinal therapeutic agents such as aluminum hydroxide, calcium carbonate, magnesium carbonate, sodium carbonate and the like; non- steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; major tranquilizers such as chloropromazine HC1, clozapine, mesoridazine, metiapine, reserpine, thioridazine and the like; micro tranquilizers such as chlordiazepoxide, diazepam, meprobamate, temezepam and the like; rhinological decongestants, sedative-hypnotics such as codeine, phenobarbital, sodium pentobarbital, sodium secobarbital and the like; other steroids such as testosterone and testosterone propionate; sulfonamides; sympathomimetic agents; vaccines; vitamins and nutrients such as the essential amino acids, essential fats and the like; antimalarials such as
  • narcotics such as codeine, dihydrocodienone, meperidine, morphine and the like
  • non-narcotics such as ⁇ ali ⁇ ylates, aspirin, acetamino ⁇ phen, d-propoxyphene and the like
  • antibiotics such as the cephalosporins, chloranphenical, gentamicin, Kanamycin A, Kanamycin B, the penicillins, ampicillin, streptomycin A, antimycin A, chloropamtheniol, metromi- dazole, oxytetracycline penicillin G, the tetracyclines, and the like
  • anti-cancer agent anti-convulsants such as mephenytoin, phenobarbital, trimethadione
  • anti- emetics such as thietylperazine
  • antihistamines such as chlorophinazine, dimenhydrinate
  • Mvcobacterium tuberculosis Herpes virus (hu onis, types 1 and 2), Candida albicans. Candida tropicalis. Trichomonas vaqinalis. Haemophilus vaginalis. Group B streptococcus E. coli. gtrep. mutans. Microplasma hominis. He ⁇ ophilus ducreyi. Granuloma inguinale, Lv phopathia venereum, Treponema pallidum. Brucella abortus,. Brucella ⁇ ieliten- sis. Brucella suis. Brucella canis. Ca pylobacter fetus. Campylobacter fetus intestinalis.
  • Leptospira pomona Listeria moncvtoqenes. Brucella ovis. Equine herpes virus 1, Equine arteritis virus, IBR-IBP virus, BVD-MB virus, Chlamvdia psittaci. Trichomonas foetus. Toxo- plasma ⁇ ondii. Escherichia coli. Actinobaccillus e uuli. Salmonella abortus ovis. Salmonella abortus e ⁇ ui. Pseudomonas aeruginosa. Corynebacterium equi. Corvnebac- terium pyogenes. Actinobaccilus seminis.
  • hormon- ally active polypeptides especially luteininzing hormone-releasing hormone (LR-RH) polypeptides, ana ⁇ logues, and antagonists thereof; mammalian growth hormones, including human, bovine, equine, and sheep growth hormones; alpha, beta, gamma, and omega interferon; interleukin I and interleukin II; and erythropoietin.
  • LR-RH luteininzing hormone-releasing hormone
  • This example describes the procedure for preparing microspheres, varying the ratio of the first non- solvent, silicone oil, to the organic ⁇ olvent, methylene chloride.
  • the polymeric coating material a copolymer with a 50:50 molar ratio of lactide:glycolide units with inherent viscosity of 0.69 dl/g, was weighed and dissolved in methylene chloride (CH 2 Cl 2 ) .
  • the ratio of the silicone oil to the methylene chloride ⁇ olvent was varied in these experiments and the result ⁇ are shown in the following Table 1.
  • the ⁇ ilicone oil cau ⁇ ed the polymer to pha ⁇ e separate, and depo ⁇ it as droplets of solvent-fluid polymer onto the surface of the water- ⁇ oluble microdroplet ⁇ . These solvent-fluid polymer droplets then coalesced to form a continuous film around the water-soluble microdroplets.
  • microspheres were then hardened by quenching by pouring the contents of this first mixture into a beaker containing heptane.
  • the heptane/methylene chloride/- ⁇ ilicone oil ⁇ olution wa ⁇ removed by filtration.
  • the microspheres were further washed with aliquots of heptane.
  • the microspheres were dried at room tempera ⁇ ture under vacuum.
  • the microsphere ⁇ obtained from this preparation were determined to have diameters ranging in size from 25 to 150 microns.
  • Table 1 gives the result ⁇ of the te ⁇ ting ⁇ to ⁇ how the effect of the ratio of eilicone oil to methylene chloride and the effect of the vi ⁇ cosity of the ⁇ ilicone oil.
  • the vi ⁇ co ⁇ ity of the ⁇ ilicone oil was studied at 200c ⁇ , 350cs, and 500cs. In three of the tests, histrelin was used as the encapsulate; with the other test ⁇ a placebo was used.
  • a 50:50 lactide:glycolide copolymer, 1.80 g, was dis ⁇ olved in 15.7 g of methylene chloride and charged to a 100 ml flask. Histrelin, 200.4 mg, was suspended in 12.2 g of methylene chloride and added with ⁇ tirring to the polymer ⁇ olution. An additional 6.0 g of methylene chloride wa ⁇ then added (total 33.9 g) . Silicone oil (350 cs), 13.13 g was added over 8.5 minutes. Then, the contents of the reaction flask were tran ⁇ ferred to 2800 ml of n-heptane with ⁇ tirring at 21*C. Stirring was continued for 3 hours.
  • micro ⁇ pheres were collected on stain ess- ⁇ teel sieves and allowed to air dry.
  • the re ⁇ idual heptane content wa ⁇ found to be 8.7% by weight.
  • the hi ⁇ trelin content was 7.76% by weight.

Abstract

This invention is the process for the preparation of microcapsules with a reduced residual solvent level, having a core compound encapsulated by a polymer coating which comprises, dissolving the polymer in an organic solvent in which the core compound is not soluble; adding the core compound; adding a first non-solvent of the polymer and core material selected from synthetic oil or vegetable oil in a ratio of first non-solvent to organic solvent of from about 1.5:1 wt/wt to about 2.5:1 wt/wt to form microcapsules; and adding a second non-solvent of the polymer. The invention is also directed to microcapsules comprising a core compound encapsulated by a polymer coating, with the microcapsule having a residual solvent content of less than one percent. The invention is particularly useful for encapsulating pharmaceutical materials in biodegradable polymers.

Description

LOW RESIDUAL SOLVENT MICROSPHERES AND MICROENCAPSULATION PROCESS
FIELD OF INVENTION
The present invention relates to a method of icroencapsulating a core material to form a microsphere with reduced residual solvent and water content.
BACKGROUND OF THE INVENTION
Microencapsulation is the process of coating a core material with a thin layer of a separate, encapsulating material to form microcapsules. The microencapsulation process has many applications, particularly in the pharmaceutical industry. In a pharmaceutical applica¬ tion, drugs are coated to obtain controlled-release of the drug, to improve chemical stability, and to permit the mixing and storage of reactive or incompatible drugs.
One of the methods of microencapsulation is a phase separation technique. For water-soluble or miscible core material, the phase separation process generally involves the technique of dispersing the solid core material of the desired particle size or an aqueous solution or suspension in a polymeric coating material dissolved in an organic solvent. The polymeric material is then deposited on the core material by gradual precipitation of the polymer.. This is achieved by either the use of precipitants, by changes in tempera¬ ture, or by removal of the solvent by dilution or distillation. An example of this process is described in United States Patent No. 4,166,800 to Fong. In this patent, the polymer is precipitated by a phase separa¬ tion agent, a non-solvent for the polymer.
U.S. Patent No. 4,518,547 to Cuff et al.. describes a process for the microencapsulation of a hydrophilic core material by interfacial polycondensation. The process comprises dissolving the core material in a hydrophilic solvent, water, preferably together with an inert carrier material and adding a water immiscible organic solvent to form droplets containing the core material. Two complementary polycondensation monomer reactants are then added either sequentially or simulta¬ neously which causes interfacial polymerization of a membrane encapsulating the core material.
U.S. Patent No. 4,384,975 to Fong describes an oil- in-water emulsion process for producing icrospheres. This process comprises dissolving a polymer in a volatile, water-immiscible organic solvent in which the core material is not soluble; adding the core material; mixing the organic dispersion with an aqueous solution containing a carboxylic acid salt as the emulsifier to form a stable oil-in-water emulsion; and removing the organic solvent by evaporation to form the micro¬ capsules.
U.S. Patent No. 4,389,330 to Tice et al.. describes a process for preparing microcapsules containing a water insoluble core material. In this process, a polymer is dissolved in an organic solvent. The core material is dispersed or dissolved in the polymer-organic solvent. This loaded mixture is then dispersed in a continuous- phase processing medium to form the microcapsules. The medium can be water or a non-aqueous media such as xylene or toluene or oils. The solvent is removed in a two-step removal process.
European Patent Application No. 81/305426.9 describes a microencapsulation process of water soluble polypeptides. In this procedure, a polymer, the wall- forming material, is dissolved in an organic solvent, methylene chloride. The core material is then added to the polymer-solvent solution. A non-solvent such as an oil compound which is soluble in the organic solvent, but is a non-solvent for the polymer is then added. In Example I, the ratio of non-solvent to organic solvent is about 1:3. The microcapsules that are formed are then quenched by mixing them with heptane.
With conventional phase separation encapsulation techniques, especially when used to microencapsulate a pharmaceutical water-soluble drug, there is a high solvent residue. A need, therefore, has continued to exist for a technique of preparing microcapsules and microspheres of high quality, with reduced residual solvent. Further, with microcapsules and microspheres encapsulated with biodegradable polymers, it is desir¬ able to avoid water in the finished product in order to enhance product stability. Water present in the biodegradable polymers will typically cause the polymers to hydrolize; for example, the mechanism of biodegrada- tion in polymers such as polylactides is by hydrolysis of ester linkages. SUMMARY OF THE INVENTION
This invention comprises a process for microencap- sulating a core material such that the resulting microcapsule has reduced residual solvent and reduced water content. In one embodiment of this invention, the microsphere has reduced residual solvent with no residual water present. The process of this invention involves the steps of:
(a) dissolving a polymeric coating material in an organic solvent in which the core material is not soluble;
(b) adding a core material;
(c) adding a first non-solvent of the polymer selected from synthetic oil or vegetable oil compounds in a ratio of first non-solvent to the organic solvent of from about 1:5 wt/wt to about 3:1 wt/wt to form embryonic microcap¬ sules; and
(d) adding a second non-solvent of the polymer to harden the embryonic microspheres and to extract the first non-solvent from the microspheres.
The invention also comprises microspheres compris¬ ing a core material encapsulated by a polymer coating, the microspheres having a residual solvent content of, about one percent.
The inventors have discovered that the use of synthetic oils or vegetable oil compounds as the first non-solvent in combination with the high ratio of the first non-solvent to the organic solvent for the polymeric coating material reduces the residual solvent in the final microsphere product. By use of this invention it is possible to reduce the level of residual solvent in the microspheres.
In one embodiment of this invention, when solid particles to be encapsulated are used, the final microspheres will have a reduced residual solvent with no residual water content. Thus, the invention also comprises microspheres comprising a core material encapsulated by a polymer coating, the microspheres having a reduced residual solvent content of about one percent and with no residual water present.
pT-TATf-Tϋr. nT-RCRIPTION OF THE PREFERRED EMBODIMENTS The process of this invention is based on a phase separation technique to microencapsulate a core materi¬ al. The general process of this invention involves the following steps:
(a) dissolving a polymeric coating material in an organic solvent;
(b) adding the core material as solid particles to form a suspension or as an aqueous solution to form a water-in-oil emulsion;
(c) adding a first non-solvent of the polymer, either synthetic oils or vegetable oils, in a ratio of first non-solvent to organic solvent of from about 1:5 wt/wt to about 3:1 wt/wt, to cause the polymer to precipitate onto the solid particles or around the water droplets to form embryonic microcapsules; and
(d) quenching with a second non-solvent of the polymer, to harden the microcapsules.
After the quenching step, the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product. By the process of this invention, a final microsphere product is produced that has a residual solvent level of less than one percent. By residual solvent is meant the level of residual second non- solvent that remains in the final microsphere product. There will also be a remaining amount of organic solvent that remains in the final microcapsule product, typi¬ cally ethylene chloride. The methylene chloride level is vacuum extractable to 0.1 % or less. As used herein, the ratios are based on a weight/weight ratio.
In the preferred embodiment of this invention, the general process of the invention involves the following steps:
(a) dissolving a polymeric coating material in an organic solvent;
(b) adding the core material as solid particles to form a suspension;
(c) adding a first non-solvent of the polymer, either synthetic oils or vegetable oils, in a ratio of first non-solvent to organic solvent of from about 1:5 wt/wt to about 3:1 wt/wt, to cause the polymer to precipitate onto the solid particles or around the water droplets to form embryonic microcapsules; and
(d) quenching with a second non-solvent of the polymer, to harden the microcapsules.
After the quenching step, the microsphere product is collected and dried under a vacuum to reduce the level of organic solvent in the final microsphere product. By the process of this invention wherein the core material is added as solid particles, a final microsphere product is produced that has a residual solvent level of less than one percent and a reduced water content. The core material that may be used in this inven¬ tion can include any material that is not soluble or miscible with the polymeric coating material or the organic solvent for the polymer or the first or second non-solvent for the polymer.
The polymeric coating material that may be used in this invention may be either natural or synthetic polymers, or combinations thereof. The polymers may include cellulosic polymers, polyvinyl acetate, poly¬ vinyl alcohol, polyvinyl chloride, natural and synthetic rubbers, polyacrylates, polyorthoesters, and the like.
Specific examples include polystyrene, ethyl- cellulose, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylaminohydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly- (meth)acrylic acid ester, polyvinylacetal-diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate- ethaσrylic acid copolymer, polycarbonate, polyesters, polypropylene, vinylchloride-vinylacetate copolymer, polysaccharides, and glycerol distearate.
Suitable polymers for use with a pharmaceutical core material include biodegradable polymers such as polyanhydrides and aliphatic polyesters including polylactide, polylactide-co-glycolide polyglycolide, polycaprolactone, polylactide-co-caprolactone, poly- hydroxybutyride, polyanhydride, polydioxanone, and copolymers thereof such as poly(lactide-co-glycolide) copolymer and polylactide homopolymer.
The organic solvent that may be used according to this invention to dissolve the polymeric coating material must be a material which will dissolve the polymeric coating material and which will not dissolve the core material to be encapsulated. If the core material is a pharmaceutical compound, then the organic solvent must also be chemically inert with respect to any pharmaceutical compounds to be encapsulated.
The organic solvent can be selected from a variety of common organic solvents including halogenated aliphatic hydrocarbons, typically the C^ to c4 halo¬ genated alkanes, such as, for example, chloroform, methylene chloride, ethylene dichloride, ethylene chloride, ethyl acetate, methylchloroform and the like; aromatic hydrocarbon compounds, halogenated aromatic hydrocarbon compounds; cyclic ethers such as tetrahydro- furan and the like.
The first non-solvent for the polymer according to this invention may be selected from synthetic oils or vegetable oil compounds. Synthetic oils may include silicone oil, mineral oil, and petroleum oils. Vege¬ table oils may include sesame oil, peanut oil, soybean oil, corn oil, cotton seed oil, coconut oil, linseed oil, and other related oils. By non-solvent is meant a solvent that is miscible with the organic solvent but is not a solvent for the polymeric coating or core materi¬ al. The inventors have discovered that the amount and type of the first non-solvent for the polymer controls the level of residual solvent (second non-solvent) in the final microsphere product. According to this invention, the ratio of first non-solvent to organic solvent is from about 1:5 to about 3:1. Further, in one embodiment of this invention, by employing solid drug particles rather than aqueous solutions or suspensions of drug, no residual water is present in the final product.
The polymeric coating material is dissolved in the selected organic solvent prior to adding the core material. The amount of polymeric coating material dissolved in the solvent is typically from about 5 to 50 percent.
The core material is then added to the polymer- solvent solution, preferably, as solid particles to form a suspension or as an aqueous solution to form a water- in-oil emulsion. The amount of core material added to the polymer-solvent solution is not critical, although the ratio of core material to polymer is important insofar as that at too high an amount of core material to polymer, microspheres will not form. Typically, the upper limit of the ratio of core material to polymer may be about 80 parts by weight core material to about 20 parts by weight polymer. There is no lower limit to the ratio at which the core material can be combined with the polymeric coating material, except that at very low loadings of core material in the microcapsules, the microcapsules would not be practically useful.
Typically in the process of this invention, core material is added to the polymer-solvent solution such that the core material comprises about 5 to 50 weight percent.
The first non-solvent, synthetic oil or vegetable oil, in an amount of the ratio of about 1:5 to about 3:0, first non-solvent to organic solvent, is then added slowly to the mixture of polymeric solvent solution with the added core material. The first non-solvent causes the polymeric material to precipitate out of the organic solvent onto the core material, thereby encapsulating the core material. The first non-solvent is added under carefully controlled conditions of temperature, rate, and stir speed. For example, temperature conditions may range from -20 degrees C to +30 degrees C; rate 5 g/minutes per g of batch; stir speed from 400 to 2500 rpm.
Following the isolation of the microspheres, the microspheres are treated in a quenching step to harden them. In this step, the microspheres are quenched with a second non-solvent. This second non-solvent hardens the microspheres and extracts the solvent from the microspheres and yet does not dissolve the microspheres (wall material or core material) .
The amount of second non-solvent added in this quenching step is typically from about 0.251/g of batch to about 1 1/g of batch. Suitable second non-solvents include heptane and aliphatic hydrocarbons such as hexanes.
After the solvent has been removed from the microspheres, the microspheres are isolated, such as by filtration or sieving, and are dried by exposure to air or by other conventional drying techniques, such as vacuum drying, drying over a dessicant, or the like. Preferably, the microspheres are dried under a vacuum at room temperature to further reduce the level of organic solvent in the final microsphere product.
As has been found from experimentation, in conven¬ tional phase-separation techniques, 5 to 10% residual solvent (heptane) is usually present in the finished product. By the process according to this invention, the residual solvent content is about one percent.
Thus, by the process of this invention a final microsphere product is produced that contains about one percent residual solvent. In the preferred embodiment, the inal microsphere product contains about one percent residual solvent with no residual water present. The microsphere product of the present invention is usually made up of particles of a spherical shape although sometimes the microspheres may be irregularly shaped. The microspheres can vary in size, ranging from sub- micron to millimeter diameters. Preferably, εubmicron to 250 urn diameters are desirable for pharmaceutical formulations allowing administration of the microspheres with a standard syringe and needle. The microspheres find utility in a wide variety of applications depending upon the encapsulated core compound. Advantageously, the microsphere product, according to this invention, is an encapsulated pharmaceutical compound which can be administered to both humans and animals.
The core material that may be used in the process of this invention may include agricultural agents, such as insecticides, fungicides, herbicides, rodenticides, pesticides, fertilizers, and viruses for crop protection and the like; cosmetic agents, such as deodorants, fragrances, and the like; food additives such as flavors; and pharmaceutical agents.
Pharmaceutical compounds are the preferred core materials of the process according to this invention. These compounds may also include the non-toxic pharma¬ ceutically acceptable acid addition salts, such as hydrochloride, εulfate, phosphate, succinate, benzoate, acetate, pamoate, fu erate, mesylate, and the like. Among the pharmaceutical drugs which may be utilized are the following: contraceptive agents including estrogens such as diethyl stilbestrol, 17-beta-estradiol, estrone, ethinyl estradiol, mestranol, and the like; progestins such as norethindrone, norgestryl, ethynodiol diacetate, lynestrenol, medroxyprogesterone acetate, dimethi- sterone, megestrol acetate, chlormadinone acetate, norgestimate, norethisterone, ethisterone, melengestrol, norethynodrel and the like; and spermicidal compounds such as nonylphenoxypolyoxyethylene glycol, benzethoniu chloride, chlorindanol and the like. Other biologically active agents which can be incorporated in the present microcapsules include gastrointestinal therapeutic agents such as aluminum hydroxide, calcium carbonate, magnesium carbonate, sodium carbonate and the like; non- steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; major tranquilizers such as chloropromazine HC1, clozapine, mesoridazine, metiapine, reserpine, thioridazine and the like; micro tranquilizers such as chlordiazepoxide, diazepam, meprobamate, temezepam and the like; rhinological decongestants, sedative-hypnotics such as codeine, phenobarbital, sodium pentobarbital, sodium secobarbital and the like; other steroids such as testosterone and testosterone propionate; sulfonamides; sympathomimetic agents; vaccines; vitamins and nutrients such as the essential amino acids, essential fats and the like; antimalarials such as 4-aminoquinolines, 8-amino- quinolines, pyrimethamine and the like; anti-migraine agents such as mazindol, phentermine and the like; anti- Parkinson agents such as L-dopa; anti-spasmodics such as atropine, methscopola ine bromide and the like; anti- spasmodics and anticholinergic agents such as bile therapy, digestants, enzymes and the like; anti-tussives such as dextromethorphan, noscapine and the like; bronchodilators, cardiovascular agents such as anti- hypertensive compounds, Rauwolfia alkaloids, coronary vasodilators, nitroglycerin, organic nitrates, penta- erythritotetranitrate and the like; electrolyte replace¬ ments such as potassium chloride, ergotalkaloids such as ergota ine with and without caffeine, hydrogenated ergot alkaloids, dihydroergocristine methanesulfate, dihydro- ergocornine ethanesulfonate, dihydroergokroyptine methanesulfate and combinations thereof, alkaloids such as atropine sulfate. Belladonna, hyoscine hydrobromide and the like; analgetics; narcotics such as codeine, dihydrocodienone, meperidine, morphine and the like; non-narcotics such as εaliσylates, aspirin, acetamino¬ phen, d-propoxyphene and the like; antibiotics such as the cephalosporins, chloranphenical, gentamicin, Kanamycin A, Kanamycin B, the penicillins, ampicillin, streptomycin A, antimycin A, chloropamtheniol, metromi- dazole, oxytetracycline penicillin G, the tetracyclines, and the like; anti-cancer agent; anti-convulsants such as mephenytoin, phenobarbital, trimethadione; anti- emetics such as thietylperazine; antihistamines such as chlorophinazine, dimenhydrinate, diphenhydramine, perphenazine, tripelennamine and the like; anti-inflam¬ matory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopuri- nol, aspirin, indomethacin, phenylbutazone and the like; prostaglandins; cytotoxic drugs such as thiotepa, chlorambucil, cyclophospha ide, melphalan, nitrogen mustard, methotrexate and the like; antigens of such microorganisms as Neisseria gonorrhea. Mvcobacterium tuberculosis. Herpes virus (hu onis, types 1 and 2), Candida albicans. Candida tropicalis. Trichomonas vaqinalis. Haemophilus vaginalis. Group B streptococcus E. coli. gtrep. mutans. Microplasma hominis. Heπophilus ducreyi. Granuloma inguinale, Lv phopathia venereum, Treponema pallidum. Brucella abortus,. Brucella πieliten- sis. Brucella suis. Brucella canis. Ca pylobacter fetus. Campylobacter fetus intestinalis. Leptospira pomona, Listeria moncvtoqenes. Brucella ovis. Equine herpes virus 1, Equine arteritis virus, IBR-IBP virus, BVD-MB virus, Chlamvdia psittaci. Trichomonas foetus. Toxo- plasma σondii. Escherichia coli. Actinobaccillus e uuli. Salmonella abortus ovis. Salmonella abortus eσui. Pseudomonas aeruginosa. Corynebacterium equi. Corvnebac- terium pyogenes. Actinobaccilus seminis. Mvσoplasma bovigenitaliu f Asperσillus fumjqatus, Absidia ramosa. Trypanosoma equiperdum. Babesia caballi. Clostridium tetani. and the like; antibodies which counteract the above microorganisms; and enzymes such as ribonuclease, neuramidinase, trypsin, glycogen phosphorylase, sperm lactic dehydrogenase, sperm hyaluronidase, adenoεsine- triphosphataεe, alkaline phoεphataεe, alkaline phospha- taεe esterase, a ino peptidase, trypsin chymotrypsin, amylase, muramidaεe, acrosomal proteinase, diesterase, glutamic acid dehydrogenase, succinic acid dehydroge¬ nase, betaglycophosphatase, lipase, ATP-ase alpha- peptate gama-glutamylotranspeptidase, εterol-3-beta-ol- dehydrogenase, DPN-di-aprorase.
Other compounds of particular interest are hormon- ally active polypeptides, especially luteininzing hormone-releasing hormone (LR-RH) polypeptides, ana¬ logues, and antagonists thereof; mammalian growth hormones, including human, bovine, equine, and sheep growth hormones; alpha, beta, gamma, and omega interferon; interleukin I and interleukin II; and erythropoietin.
Having generally described the invention, further understanding can be obtained by reference to certain specific examples which are provided herein for purpose of illustration only and are not intended to be limiting unless otherwise specified. EXΑMPIJ5 I
This example describes the procedure for preparing microspheres, varying the ratio of the first non- solvent, silicone oil, to the organic εolvent, methylene chloride.
The polymeric coating material, a copolymer with a 50:50 molar ratio of lactide:glycolide units with inherent viscosity of 0.69 dl/g, was weighed and dissolved in methylene chloride (CH2Cl2) . The encapsu¬ late, histrelin, was dispersed in the solvent/polymer mixture using a stirrer. With continued stirring, silicone oil waε added to the mixture. The ratio of the silicone oil to the methylene chloride εolvent was varied in these experiments and the resultε are shown in the following Table 1. The εilicone oil cauεed the polymer to phaεe separate, and depoεit as droplets of solvent-fluid polymer onto the surface of the water- εoluble microdropletε. These solvent-fluid polymer droplets then coalesced to form a continuous film around the water-soluble microdroplets.
The microspheres were then hardened by quenching by pouring the contents of this first mixture into a beaker containing heptane. The heptane/methylene chloride/- εilicone oil εolution waε removed by filtration. The microspheres were further washed with aliquots of heptane. The microspheres were dried at room tempera¬ ture under vacuum. The microsphereε obtained from this preparation were determined to have diameters ranging in size from 25 to 150 microns.
The following Table 1 gives the resultε of the teεtingε to εhow the effect of the ratio of eilicone oil to methylene chloride and the effect of the viεcosity of the εilicone oil. The viεcoεity of the εilicone oil was studied at 200cε, 350cs, and 500cs. In three of the tests, histrelin was used as the encapsulate; with the other testε a placebo was used.
Figure imgf000018_0001
* Vacuum extractable to 0.8%
** Loaded encapsulate = histrelin
EXAMPLE II
■Silicone Oil 1:2.6 Ratio rwt/wt. of First Non-Solvent to Solvent
A 50:50 lactide:glycolide copolymer, 1.80 g, was disεolved in 15.7 g of methylene chloride and charged to a 100 ml flask. Histrelin, 200.4 mg, was suspended in 12.2 g of methylene chloride and added with εtirring to the polymer εolution. An additional 6.0 g of methylene chloride waε then added (total = 33.9 g) . Silicone oil (350 cs), 13.13 g was added over 8.5 minutes. Then, the contents of the reaction flask were tranεferred to 2800 ml of n-heptane with εtirring at 21*C. Stirring was continued for 3 hours. The microεpheres were collected on stain ess-εteel sieves and allowed to air dry. The reεidual heptane content waε found to be 8.7% by weight. The hiεtrelin content was 7.76% by weight.
E AMP ; HT
Silicone Oil 1.9:1 Ratio of First Non-Solvent to Solvent
1.8 g of a 50:50 lactiderglycolide copolymer was dissolved in 15.0 g of methylene chloride. Histrelin, 201.5 mg, was suspended in 15.0 g of methylene chloride and sonicated briefly to disperse the drug. The disperεion waε then added with εtirring to the polymer εolution. An additional 12.67 g of methylene chloride waε added to the reaction flaεk. Silicone oil (350 cs) , 82.17 g, was added over 13 minutes. The contents of the reaction flaεk were tranεferred to 3250 ml of n-heptane with εtirring at 18.2*C. Stirring waε continued for 3 hourε. The microcapεuleε were collected on εtainless- εteel sieves and allowed to air dry. Reεidual heptane waε found to be 0.9% by weight. Hiεtrelin content was 8.35% by weight.
The foregoing invention has been deεcribed in some detail by way of illustration and example for purposes of clarity and understanding. It will be obvious that certain changes and modifications may be practiced within the scope of the invention, aε limited only by εcope of the appended claims.

Claims

WHAT Ig CLAIMED IS:
1. A process for the preparation of microspheres comprising a core material encapsulated by a polymer coating comprising:
(a) dissolving a polymer coating material in an organic solvent in which the core material iε not soluble to form a polymer-organic εolvent mixture;
(b) adding the core material to said mixture;
(c) adding a first non-solvent of the polymer selected from εynthetic oil or vegetable oil in a ratio of first non-solvent to organic solvent of from about 1.5:1 wt/wt to about 3:1 wt/wt to the core material- containing mixture to form embryonic microspheres; and
(d) quenching said embryonic microspheres with a second non-solvent of the polymer to produce microspheres.
2. The process of claim 1 wherein said polymer coating material is selected from the group consiεting of celluloεic polymerε, polyvinyl acetate, polyvinyl alcohol, polyvinyl chloride, natural and εynthetic rubberε, polyacrylateε and polyorthoesters.
3. The process of claim 1 wherein said polymer coating material iε εelected from the group consisting of polystyrene, ethyicellulose, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylaminohydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly(meth)acrylic acid ester, poly- vinylacetal-diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate-methacrylic acid copolymer, polycarbonate, polyeεterε, polypropylene, vinylchloride- vinylacetate copolymer, polysaccharides, and glycerol diεtearate.
4. The process of claim 1 wherein εaid polymer coating material iε a biodegradable polymer selected from the group consiεting of polylactide, polylactide- co-glycolide polyglycolide, polycaprolactone, poly- lactide-co-caprolactone, polyhydroxybutyride, poly- anhydride, polydioxanone, and copolymerε thereof.
5. The proceεε of claim 1 wherein the polymer coating material iε a selected from the group consiεting of poly(lactide-co-glycolide) and polylactide.
6. The proceεs of claim 1 wherein said organic solvent is selected from chloroform, methylene chloride, tetrahydrofuran, and ethyl acetate.
7. The process of claim 1 wherein εaid firεt non- εolvent iε selected from silicone oil, mineral oil, petroleum oil, εeεame oil, peanut oil, εoybean oil, corn oil, cotton seed oil, coconut oil, and linseed oil.
8. The process of claim 6 wherein εaid first non- solvent is εeεame oil or εilicone oil.
9. The proceεs of claim 1 wherein εaid εecond non-εolvent iε εelected from heptane, hexaneε or pentane.
10. The proceεε of claim 1 wherein said core material compriseε solid particles and is added to εaid mixture in εtep (b) to form a εuspension.
11. The procesε of claim 1 wherein εaid core material comprises an aqueous solution and iε added to εaid mixture in εtep (b) to form a water-in-oil emul¬ sion..
12. The proceεε of claim 1 further compriεing treating εaid microεphere product by drying εaid microsphere product under a vacuum.
13. A procesε for producing microεphereε compriε¬ ing a core material encapsulated by a polymer coating wherein said microsphereε contain leεs than one percent residual εolvent and with no residual water content, comprising:
(a) disεolving a polymer coating material in an organic εolvent in which the core material iε not soluble to form a polymer-organic εolvent mixture;
(b) adding the core compound aε εolid particles to said mixture to form a suspension;
(c) adding a first non-εolvent of the polymer selected from εynthetic oil or vegetable oil in a ratio of first non-solvent to organic solvent of from about 1.5:1 wt/wt to about 3:1 wt/wt to the core material- containing mixture to form embryonic microcapsuleε; and
(d) quenching said embryonic microcapsules with a second non-solvent of the polymer to produce a final product containing about one percent residual εolvent.
14. Microcapεuleε produced by the proceεε of any of claims 1-13.
15. A microsphere comprising a core material encapsulated by a polymer coating, said microsphere having a residual εolvent content of one percent or leεε.
16. The microsphere of claim 15 wherein εaid polymer iε selected from the group consiεting of celluloεic polymerε, polyvinyl acetate, polyvinyl alcohol, polyvinyl chloride, natural and εynthetic rubbers, polyacrylates and polyorthoesters.
17. The microsphere of claim 15 wherein said polymer is selected from the group consiεting of polyεtyrene, ethylcelluloεe, cellulose acetate, hydroxy propylmethyl cellulose, cellulose acetate, dibutylamino- hydroxypropyl ether, polyvinyl butyral, polyvinyl formal, poly(meth)acrylic acid ester, polyvinylacetal- diethylamino acetate, 2-methyl-5-vinyl pyridine, methacrylate-methacrylic acid copolymer, polycarbonate, polyesterε, polypropylene, vinylchloride-vinylacetate copolymer, polysaccharideε, and glycerol diεtearate.
18. The microεphere of claim 15 wherein εaid polymer iε a biodegradable polymer εelected from the group conεiεting of polylactide, polylactide-co-glyco- lide polyglycolide, polycaprolactone, polylactide-co- caprolactone, polyhydroxybutyride, polyanhydride, polydioxanone, and copolymerε thereof.
19. The microεphere of claim 15 wherein εaid core material iε a luteinizing hormone-releasing hormone (LH- RH) peptide, analog, or antagoniεt.
20. The microεphere of claim 15 wherein said core material is growth hormone.
21. The microsphere of claim 15 wherein εaid core material is alpha, beta, gamma, or omega interferon.
22. The microεphere of claim 15 wherein said core material iε erythropoietin.
22. The microεphere of claim 15 wherein said core material iε interleukin I or interleukin II.
PCT/US1988/003859 1987-10-30 1988-10-31 Low residual solvent microspheres and microencapsulation process WO1989003678A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11492187A 1987-10-30 1987-10-30
US114,921 1987-10-30

Publications (1)

Publication Number Publication Date
WO1989003678A1 true WO1989003678A1 (en) 1989-05-05

Family

ID=22358249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003859 WO1989003678A1 (en) 1987-10-30 1988-10-31 Low residual solvent microspheres and microencapsulation process

Country Status (2)

Country Link
AU (1) AU2810189A (en)
WO (1) WO1989003678A1 (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000070A1 (en) * 1991-06-28 1993-01-07 Endorecherche Inc. Controlled release systems and low dose androgens
EP0543841A4 (en) * 1990-07-13 1993-03-01 Du Pont Degradable resins for electrostatic liquid developers.
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
EP0576377A1 (en) * 1992-06-24 1993-12-29 FLAMEL TECHNOLOGIES, Société Anonyme Microcapsules containing at least an active principle, their applications and one of their processes of preparation
US5362720A (en) * 1991-06-28 1994-11-08 Endorecherche, Inc. Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5654008A (en) * 1993-11-19 1997-08-05 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
WO1998007442A1 (en) * 1996-08-23 1998-02-26 International Centre For Genetic Engineering And Biotechnology Sustained-release preparation comprising erythropoietin and polylactide coglycolide
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1999036071A1 (en) * 1998-01-19 1999-07-22 Korea Research Institute Of Chemical Technology Biodegradable polymer matrices for sustained delivery of anesthetics
WO1999036057A1 (en) * 1998-01-19 1999-07-22 Korea Research Institute Of Chemical Technology Controlled releasing antibiotics preparation
WO1999047588A1 (en) * 1998-03-14 1999-09-23 Cenes Drug Delivery Limited Production of microparticles
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
AT406017B (en) * 1993-05-15 2000-01-25 Sod Conseils Rech Applic METHOD FOR PRODUCING PARTICLES, PARTICULAR OBTAINED, AND PHARMACEUTICAL MEASURES CONTAINING SUCH PARTICLES
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6379704B2 (en) 2000-05-19 2002-04-30 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6379703B1 (en) 1998-12-30 2002-04-30 Alkermes Controlled Therapeutics Inc., Ii Preparation of microparticles having a selected release profile
EP1234670A2 (en) 2001-02-27 2002-08-28 Imaje S.A. Printhead and printer with improved deflection electrodes
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6830737B2 (en) 2000-09-27 2004-12-14 Alkermes Controlled Therapeutics Inc. Ii Apparatus for preparing microparticles using liquid-liquid extraction
EP1728550A1 (en) * 2004-03-23 2006-12-06 Kyowa Hakko Kogyo Co., Ltd. Method for producing coated fine particles
US7247319B2 (en) 2000-12-27 2007-07-24 Alkermes, Inc. Preparation of microparticles having improved flowability
US8877252B2 (en) 2004-04-15 2014-11-04 Alkermes Pharma Ireland Limited Polymer-based sustained release device
WO2016007468A1 (en) * 2014-07-07 2016-01-14 AntriaBio Solvent extraction from biodegradable microparticles
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN108969494A (en) * 2018-09-25 2018-12-11 珠海赛隆药业股份有限公司 A kind of Parecoxib Sodium durative action preparation and preparation method thereof
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10363287B2 (en) 2005-02-03 2019-07-30 Intarcia Therapeutics, Inc. Method of manufacturing an osmotic delivery device
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10441528B2 (en) 2008-02-13 2019-10-15 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2021010814A3 (en) * 2019-07-15 2021-04-15 Dva Farma Mexicana S.A. De C.V. Compositions of film coatings for tablets with increased gloss, method for production thereof and application of same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3971852A (en) * 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
US4244836A (en) * 1978-02-07 1981-01-13 Hoechst Aktiengesellschaft Process for manufacturing microcapsules of polyvinyl alcohol with liquid water-insoluble content
US4389331A (en) * 1979-10-31 1983-06-21 Tanabe Seiyaku Co., Ltd. Process for preparing pharmaceutically active compound-containing microcapsules
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
EP0052510B1 (en) * 1980-11-18 1986-08-27 Syntex (U.S.A.) Inc. Microencapsulation of water soluble polypeptides
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
US4673595A (en) * 1984-10-17 1987-06-16 Debiopharm, S.A. Microencapsulation by phase separation of water-soluble medicaments
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4711782A (en) * 1983-11-04 1987-12-08 Takeda Chemical Industries, Ltd. Prolonged release microcapsules and their production
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4766012A (en) * 1985-08-29 1988-08-23 Farmaceutici Formenti S.P.A. Microencapsulation of a medicament

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3971852A (en) * 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
US4244836A (en) * 1978-02-07 1981-01-13 Hoechst Aktiengesellschaft Process for manufacturing microcapsules of polyvinyl alcohol with liquid water-insoluble content
US4389331A (en) * 1979-10-31 1983-06-21 Tanabe Seiyaku Co., Ltd. Process for preparing pharmaceutically active compound-containing microcapsules
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
EP0052510B1 (en) * 1980-11-18 1986-08-27 Syntex (U.S.A.) Inc. Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
US4711782A (en) * 1983-11-04 1987-12-08 Takeda Chemical Industries, Ltd. Prolonged release microcapsules and their production
US4673595A (en) * 1984-10-17 1987-06-16 Debiopharm, S.A. Microencapsulation by phase separation of water-soluble medicaments
US4766012A (en) * 1985-08-29 1988-08-23 Farmaceutici Formenti S.P.A. Microencapsulation of a medicament
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543841A1 (en) * 1990-07-13 1993-06-02 E.I. Du Pont De Nemours And Company Degradable resins for electrostatic liquid developers
EP0543841A4 (en) * 1990-07-13 1993-03-01 Du Pont Degradable resins for electrostatic liquid developers.
US5753639A (en) * 1991-06-28 1998-05-19 Endorecherche Inc. Low dose androgenic compounds for prevention and treatment of endometriosis
US5629303A (en) * 1991-06-28 1997-05-13 Endorecherche Inc. Controlled release systems and low dose androgens
WO1993000070A1 (en) * 1991-06-28 1993-01-07 Endorecherche Inc. Controlled release systems and low dose androgens
US5545634A (en) * 1991-06-28 1996-08-13 Endorecherche, Inc. Activation of androgen receptors with low dose non-masculinizing androgenic compounds
US5362720A (en) * 1991-06-28 1994-11-08 Endorecherche, Inc. Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds
US5434146A (en) * 1991-06-28 1995-07-18 Endorecherche, Inc. Controlled release systems and low dose androgens
US5541172A (en) * 1991-06-28 1996-07-30 Endorecherche, Inc. Controlled release systems and low dose androgens
US5846960A (en) * 1991-06-28 1998-12-08 Endorecherche, Inc. Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds
US5567695A (en) * 1991-06-28 1996-10-22 Endorecherche, Inc. Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds
US5861387A (en) * 1991-06-28 1999-01-19 Endorecherche Inc. Controlled release systems and low dose androgens
US6749866B2 (en) 1992-03-12 2004-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6368630B1 (en) 1992-03-12 2002-04-09 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
AU698016B2 (en) * 1992-06-11 1998-10-22 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
EP0576377A1 (en) * 1992-06-24 1993-12-29 FLAMEL TECHNOLOGIES, Société Anonyme Microcapsules containing at least an active principle, their applications and one of their processes of preparation
FR2692812A1 (en) * 1992-06-24 1993-12-31 Flamel Tech Sa Microcapsules containing at least one active principle, their applications and process for preparing microcapsules containing at least one active principle.
US5585050A (en) * 1992-06-24 1996-12-17 Flamel Technologies Microcapsules containing at least one active ingredient, application of such capsules and one of their preparation methods
AT406017B (en) * 1993-05-15 2000-01-25 Sod Conseils Rech Applic METHOD FOR PRODUCING PARTICLES, PARTICULAR OBTAINED, AND PHARMACEUTICAL MEASURES CONTAINING SUCH PARTICLES
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5654008A (en) * 1993-11-19 1997-08-05 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US6358443B1 (en) 1995-05-18 2002-03-19 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6726860B2 (en) 1995-05-18 2004-04-27 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US7037450B2 (en) 1995-05-18 2006-05-02 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6153129A (en) * 1995-05-18 2000-11-28 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5916598A (en) * 1996-05-07 1999-06-29 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US6110503A (en) * 1996-05-07 2000-08-29 Alkermes Controlled Therapeutics Inc. Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6403114B1 (en) 1996-05-07 2002-06-11 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
WO1998007442A1 (en) * 1996-08-23 1998-02-26 International Centre For Genetic Engineering And Biotechnology Sustained-release preparation comprising erythropoietin and polylactide coglycolide
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999036071A1 (en) * 1998-01-19 1999-07-22 Korea Research Institute Of Chemical Technology Biodegradable polymer matrices for sustained delivery of anesthetics
WO1999036057A1 (en) * 1998-01-19 1999-07-22 Korea Research Institute Of Chemical Technology Controlled releasing antibiotics preparation
WO1999047588A1 (en) * 1998-03-14 1999-09-23 Cenes Drug Delivery Limited Production of microparticles
US6596316B2 (en) 1998-12-30 2003-07-22 Alkermes Controlled Therapeutics, Inc. Ii Preparation of microparticles having a selected release profile
US6379703B1 (en) 1998-12-30 2002-04-30 Alkermes Controlled Therapeutics Inc., Ii Preparation of microparticles having a selected release profile
US6861016B2 (en) 1999-11-12 2005-03-01 Alkermes Controlled Therapeutics Inc. Ii Apparatus and method for preparing microparticles
US7300671B2 (en) 1999-11-12 2007-11-27 Alkermes, Inc. Method and apparatus for preparing microparticles using in-line solvent extraction
US7510730B2 (en) 1999-11-12 2009-03-31 Alkermes, Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6537586B2 (en) 1999-11-12 2003-03-25 Alkermes Controlled Therapeutics Inc. Ii Apparatus and method for preparing microparticles
US6540393B1 (en) 1999-11-12 2003-04-01 Alkermes Controlled Therapeutics Inc. Ii Apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6395304B2 (en) 1999-11-12 2002-05-28 Alkermes Controlled Therapeutics Inc. Ii Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6713090B2 (en) 1999-11-12 2004-03-30 Alkermas Controlled Therapeutics Inc. Ii Apparatus and method for preparing microparticles
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6939033B2 (en) 1999-11-12 2005-09-06 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6379704B2 (en) 2000-05-19 2002-04-30 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6534092B2 (en) 2000-05-19 2003-03-18 Alkermes Controlled Therapeutics, Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US7799345B2 (en) 2000-05-25 2010-09-21 Alkermes Controlled Therapeutics, Inc. Preparation of injectable suspensions having improved injectability
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6667061B2 (en) 2000-05-25 2003-12-23 Alkermes Controlled Therapeutics, Inc. Preparation of injectable suspensions having improved injectability
US7371406B2 (en) 2000-05-25 2008-05-13 Alkermes Controlled Therapeutics, Inc. Preparation of injectable suspensions having improved injectability
US6830737B2 (en) 2000-09-27 2004-12-14 Alkermes Controlled Therapeutics Inc. Ii Apparatus for preparing microparticles using liquid-liquid extraction
US6884372B2 (en) 2000-09-27 2005-04-26 Alkermes Controlled Therapeutics, Inc. Ii Method for preparing microparticles using liquid-liquid extraction
US7247319B2 (en) 2000-12-27 2007-07-24 Alkermes, Inc. Preparation of microparticles having improved flowability
EP1234670A2 (en) 2001-02-27 2002-08-28 Imaje S.A. Printhead and printer with improved deflection electrodes
JP2011037882A (en) * 2001-08-31 2011-02-24 Alkermes Inc Method for extracting residual solvent and microparticle produced thereby
JP2013216676A (en) * 2001-08-31 2013-10-24 Alkermes Pharma Ireland Ltd Residual solvent extraction method, and microparticle prepared by the same
US7223440B2 (en) 2001-08-31 2007-05-29 Alkermes, Inc. Residual solvent extraction method and microparticles produced thereby
JP2015227383A (en) * 2001-08-31 2015-12-17 アルカームズ ファーマ アイルランド リミテッド Residual solvent extraction method and microparticles produced thereby
US7524530B2 (en) 2001-08-31 2009-04-28 Alkermes, Inc. Residual solvent extraction method and microparticles produced thereby
JP2005502674A (en) * 2001-08-31 2005-01-27 アルカームズ コントロールド セラピューティクス,インコーポレイテッド ツー Residual solvent extraction method and fine particles produced by the same
US7875310B2 (en) 2001-08-31 2011-01-25 Alkermes, Inc. Residual solvent extraction method and microparticles produced thereby
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US8187672B2 (en) 2001-08-31 2012-05-29 Alkermes Pharma Ireland Limited Residual solvent extraction method and microparticles produced thereby
EP1728550A1 (en) * 2004-03-23 2006-12-06 Kyowa Hakko Kogyo Co., Ltd. Method for producing coated fine particles
EP1728550A4 (en) * 2004-03-23 2007-09-05 Kyowa Hakko Kogyo Kk Method for producing coated fine particles
US8877252B2 (en) 2004-04-15 2014-11-04 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US9238076B2 (en) 2004-04-15 2016-01-19 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US10363287B2 (en) 2005-02-03 2019-07-30 Intarcia Therapeutics, Inc. Method of manufacturing an osmotic delivery device
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US10441528B2 (en) 2008-02-13 2019-10-15 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10869830B2 (en) 2009-09-28 2020-12-22 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
WO2016007468A1 (en) * 2014-07-07 2016-01-14 AntriaBio Solvent extraction from biodegradable microparticles
US10137089B2 (en) 2014-07-07 2018-11-27 Rezolute, Inc Solvent extraction from biodegradable microparticles
AU2015288014C1 (en) * 2014-07-07 2020-07-16 Rezolute, Inc. Solvent extraction from biodegradable microparticles
US9532953B2 (en) 2014-07-07 2017-01-03 Antriabio, Inc. Solvent extraction from biodegradable microparticles
AU2015288014B2 (en) * 2014-07-07 2020-04-16 Rezolute, Inc. Solvent extraction from biodegradable microparticles
US9439864B2 (en) 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10583080B2 (en) 2014-09-30 2020-03-10 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US11214607B2 (en) 2016-05-16 2022-01-04 Intarcia Therapeutics Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US11840559B2 (en) 2016-05-16 2023-12-12 I2O Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD912249S1 (en) 2016-06-02 2021-03-02 Intarcia Therapeutics, Inc. Implant removal tool
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
USD962433S1 (en) 2016-06-02 2022-08-30 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11654183B2 (en) 2017-01-03 2023-05-23 Intarcia Therapeutics, Inc. Methods comprising continuous administration of exenatide and co-administration of a drug
CN108969494A (en) * 2018-09-25 2018-12-11 珠海赛隆药业股份有限公司 A kind of Parecoxib Sodium durative action preparation and preparation method thereof
WO2021010814A3 (en) * 2019-07-15 2021-04-15 Dva Farma Mexicana S.A. De C.V. Compositions of film coatings for tablets with increased gloss, method for production thereof and application of same

Also Published As

Publication number Publication date
AU2810189A (en) 1989-05-23

Similar Documents

Publication Publication Date Title
WO1989003678A1 (en) Low residual solvent microspheres and microencapsulation process
US4389330A (en) Microencapsulation process
US5916598A (en) Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
EP0729353B1 (en) Preparation of biodegradable microparticles containing a biologically active agent
Tice et al. Preparation of injectable controlled-release microcapsules by a solvent-evaporation process
DE69928283T2 (en) PREPARATION OF MICROPARTICLES WITH A SELECTED RELEASE PROFILE
US5650173A (en) Preparation of biodegradable microparticles containing a biologically active agent
EP1210942A2 (en) Microparticles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE